日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study

奥洛莫拉西布(一种新一代 KRAS G12C 抑制剂)在 KRAS G12C 突变型晚期实体瘤中的泛肿瘤活性:一项首次人体研究

Murciano-Goroff, Yonina R; Hollebecque, Antoine; Heist, Rebecca S; Cassier, Philippe A; Han, Ji-Youn; Kim, So Yeon; Sabari, Joshua K; Tosi, Diego; Sacher, Adrian; Burns, Timothy F; Shimizu, Toshio; Reddy Ammakkanavar, Natraj; Spira, Alexander; Gomez-Roca, Carlos; Patnaik, Amita; Cosman, Rasha; Bodor, J Nicholas; Nagasaka, Misako; You, Arthur Xintian; McNeely, Samuel C; Peter, Raimund; Fink, Aaron; Chen, Aaron; Oxnard, Geoffrey R; Willard, Melinda D; Kuboki, Yasutoshi; Koyama, Takafumi

A genome-wide association study identifies the GPM6A locus associated with age at onset in ALS

全基因组关联研究发现,GPM6A基因位点与肌萎缩侧索硬化症(ALS)的发病年龄相关。

Nakamura, Ryoichi; Tohnai, Genki; Atsuta, Naoki; Matsuda, Yumi; Morimoto, Satoru; Ito, Daisuke; Katsuno, Masahisa; Izumi, Yuishin; Morita, Mitsuya; Iwata, Ikuko; Yabe, Ichiro; Nakazato, Tomoko; Hattori, Nobutaka; Hirayama, Takehisa; Kano, Osamu; Tamura, Asako; Suzuki, Naoki; Aoki, Masashi; Shibuya, Kazumoto; Kuwabara, Satoshi; Oda, Masaya; Hashimoto, Rina; Aiba, Ikuko; Ishihara, Tomohiko; Onodera, Osamu; Yamashita, Toru; Ishiura, Hiroyuki; Bokuda, Kota; Shimizu, Toshio; Ikeda, Yoshio; Hasegawa, Kazuko; Tanaka, Fumiaki; Yokota, Takanori; Kanai, Kazuaki; Noto, Yu-Ichi; Kaji, Ryuji; Watanabe, Hirohisa; Konishi, Tomoko; Hasegawa, Mikiko; Fukaya, Hozuki; Niwa, Jun-Ichi; Doyu, Manabu; Okada, Yohei; Nakamura, Shiho; Ozawa, Fumiko; Okano, Hideyuki; Nakatochi, Masahiro; Sobue, Gen

Barriers to publishing early phase clinical trials: the oncologists' perspective

早期临床试验发表的障碍:肿瘤学家的视角

Lucassen, Merel J J; Bergmann, Pedro; Husson, Olga; Banerji, Udai; Basu, Bristi; Melero, Ignacio; Calvo, Emiliano; Cassier, Philippe A; Drilon, Alexander; Fong, Peter C; Garralda, Elena; Joshua, Anthony M; Lin, Chia-Chi; Lopez, Juanita; Moreno, Victor; Minchom, Anna; Plummer, Ruth; Postel-Vinay, Sophie; Spreafico, Anna; Shimizu, Toshio; Yap, Timothy A; Yap, Christina; De Bono, Johann S; Steeghs, Neeltje

Pharmacokinetic and Exposure-Response Modeling Support Body Surface Area-Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors

药代动力学和暴露-反应模型支持基于体表面积的法妥珠单抗依克立布林给药方案用于日本实体瘤患者

Hayato, Seiichi; Hamuro, Lora; Shimizu, Toshio; Yonemori, Kan; Nishio, Shin; Yunokawa, Mayu; Yoshida, Tatsuya; Nishio, Makoto; Matsumoto, Koji; Takehara, Kazuhiro; Hasegawa, Kosei; Kozuki, Toshiyuki; Hirashima, Yasuyuki; Kato, Hidenori; Miura, Takuma; Nomoto, Maiko; Zhao, Yue; Zhu, Li; Yasuda, Sanae

Comparison of the Immune Checkpoint InhibitorFree Survival Between Patients Who Completed and Those Who Discontinued ICI for Non-Small Cell Lung Cancer

比较完成免疫检查点抑制剂治疗的非小细胞肺癌患者与停止免疫检查点抑制剂治疗的非小细胞肺癌患者的无免疫检查点抑制剂生存期

Nagai, Takahiro; Akamatsu, Hiroaki; Takase, Eri; Murakami, Eriko; Sugimoto, Takeya; Shibaki, Ryota; Hayata, Atsushi; Shimizu, Toshio; Nakanishi, Masanori; Koh, Yasuhiro; Yamamoto, Nobuyuki

Discrepancy between preoperative noninvasive evaluation and intraoperative electrical cortical stimulation for motor function assessment in diffuse cortical dysplasia

弥漫性皮质发育不良患者术前无创评估与术中皮层电刺激运动功能评估结果的差异

Onoda, Ryo; Fujimoto, So; Bokuda, Kota; Shimizu, Toshio; Matsuo, Takeshi

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Datopotamab Deruxtecan 治疗晚期或转移性 HR+/HER2- 和三阴性乳腺癌:来自 I 期 TROPION-PanTumor01 研究的结果

Bardia, Aditya; Krop, Ian E; Kogawa, Takahiro; Juric, Dejan; Tolcher, Anthony W; Hamilton, Erika P; Mukohara, Toru; Lisberg, Aaron; Shimizu, Toshio; Spira, Alexander I; Tsurutani, Junji; Damodaran, Senthil; Papadopoulos, Kyriakos P; Greenberg, Jonathan; Kobayashi, Fumiaki; Zebger-Gong, Hong; Wong, Rie; Kawasaki, Yui; Nakamura, Tadakatsu; Meric-Bernstam, Funda

Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors

Simlukafusp Alfa (FAP-IL2v) 联合或不联合 Atezolizumab 治疗日本晚期实体瘤患者的 I 期研究

Koyama, Takafumi; Yonemori, Kan; Shimizu, Toshio; Sato, Jun; Kondo, Shunsuke; Sudo, Kazuki; Yoshida, Tatsuya; Katsuya, Yuki; Imaizumi, Tatsuki; Enomoto, Masashi; Seki, Ryoko; Yamamoto, Noboru

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors

利维莫尼普利单抗(一种靶向 GARP:TGF-β1 复合物的抗体)作为单药疗法以及与抗 PD-1 抗体布迪加利单抗联合疗法治疗晚期实体瘤患者的首次人体 1 期剂量递增试验结果

Shimizu, Toshio; Powderly, John; Abdul Razak, Albiruni; LoRusso, Patricia; Miller, Kathy D; Kao, Steven; Kongpachith, Sarah; Tribouley, Catherine; Graham, Michelle; Stoll, Brian; Patel, Maulik; Sahtout, Mohammad; Blaney, Martha; Leibman, Rachel; Golan, Talia; Tolcher, Anthony

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors

更正:针对 GARP:TGF-β1 复合物的抗体 livmoniplimab 作为单药疗法以及与抗 PD-1 抗体 budigalimab 联合疗法治疗晚期实体瘤患者的首次人体 1 期剂量递增结果

Shimizu, Toshio; Powderly, John; Abdul Razak, Albiruni; LoRusso, Patricia; Miller, Kathy D; Kao, Steven; Kongpachith, Sarah; Tribouley, Catherine; Graham, Michelle; Stoll, Brian; Patel, Maulik; Sahtout, Mohammad; Blaney, Martha; Leibman, Rachel; Golan, Talia; Tolcher, Anthony